N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Matthew McCallum(University of Washington), Anna De Marco(Vir Biotechnology (Switzerland)), Florian A. Lempp(VIR Biotechnology (United States)), M. Alejandra Tortorici(Centre National de la Recherche Scientifique), Dora Pinto(Vir Biotechnology (Switzerland)), Alexandra C. Walls(University of Washington), Martina Beltramello(Vir Biotechnology (Switzerland)), Alex Chen(VIR Biotechnology (United States)), Zhuoming Liu(Washington University in St. Louis), Fabrizia Zatta(Vir Biotechnology (Switzerland)), Samantha K. Zepeda(University of Washington), Julia di Iulio(VIR Biotechnology (United States)), John E. Bowen(University of Washington), Martin Montiel-Ruiz(VIR Biotechnology (United States)), Jiayi Zhou(VIR Biotechnology (United States)), Laura E. Rosen(VIR Biotechnology (United States)), Siro Bianchi(Vir Biotechnology (Switzerland)), Barbara Guarino(Vir Biotechnology (Switzerland)), Chiara Silacci Fregni(Vir Biotechnology (Switzerland)), Rana Abdelnabi(Rega Institute for Medical Research), Caroline S. Foo(Rega Institute for Medical Research), Paul W. Rothlauf(Washington University in St. Louis), Louis-Marie Bloyet(Washington University in St. Louis), Fabio Benigni(Vir Biotechnology (Switzerland)), Elisabetta Cameroni(Vir Biotechnology (Switzerland)), Johan Neyts(Rega Institute for Medical Research), Agostino Riva(University of Milan), Gyorgy Snell(VIR Biotechnology (United States)), Amalio Telenti(VIR Biotechnology (United States)), Sean P. J. Whelan(Washington University in St. Louis), Herbert W. Virgin(VIR Biotechnology (United States)), Davide Corti(Vir Biotechnology (Switzerland)), Matteo Samuele Pizzuto(Vir Biotechnology (Switzerland)), David Veesler(University of Washington)
Cell
March 18, 2021
Cited by 1,017Open Access
Full Text

Abstract


Related Papers